A Phase III, Randomized, Double-Blind, Multi-center Study to Investigate the Efficacy and Safety of Camrelizumab+Gemcitabine+Cisplatin Versus Placebo+Gemcitabine+Cisplatin in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma
Latest Information Update: 13 Apr 2020
At a glance
- Drugs Camrelizumab (Primary) ; Cisplatin; Gemcitabine
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 08 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 17 Dec 2018 Status changed from not yet recruiting to recruiting.
- 25 Oct 2018 New trial record